Chlorambucil (Leukeran)

General information

Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Chronic lymphocytic leukemia
• Hodgkin lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Waldenström macroglobulinemia

Patient drug information

• Chlorambucil (Leukeran) patient drug information (Chemocare)
• Chlorambucil (Leukeran) patient drug information (UpToDate)

History of changes in FDA indication

• 3/18/1957: Initial FDA approval
• 11/13/2003: (earliest label available on Drugs@FDA) indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Also known as

• Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan